E. Iwama

Y. Nakanishi, K. Azuma, I. Okamoto, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non‐small‐cell lung cancer

T. Mushiroda, K. Tsuchihashi, H. Saya, 2017, Cancer science.

Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae

E. Baba, Y. Nakanishi, K. Takayama, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.

Y. Nakanishi, K. Takayama, I. Okamoto, 2015, Cancer genetics.

Oncotargets and Therapy Dovepress

Y. Nakanishi, K. Takayama, I. Okamoto, 2022 .

Induction of PD-L 1 Expression by the EML 4 – ALK Oncoprotein andDownstreamSignalingPathways in Non – Small Cell Lung Cancer

Y. Nakanishi, K. Takayama, K. Azuma, 2015 .

Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

Y. Nakanishi, K. Takayama, I. Okamoto, 2015, Investigational New Drugs.

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

K. Goto, K. Nishio, Y. Nakanishi, 2018, Cancer science.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Kaoru Tanaka, K. Nishio, K. Azuma, 2019, Scientific Reports.

Evaluation of Patient Education System to Improve Their Understanding in Patients Treated with Erlotinib or Gefitinib

K. Takayama, S. Masuda, H. Ikesue, 2015 .

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

Y. Nakanishi, K. Azuma, I. Okamoto, 2017, Oncotarget.

Clinical benefits associated with first line treatment using afatinib

I. Okamoto, E. Iwama, 2015 .

Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

K. Akashi, Y. Nakanishi, I. Okamoto, 2017, Respiratory investigation.

Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.

Y. Nakanishi, I. Okamoto, H. Kohrogi, 2016, Lung cancer.

Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR

E. Baba, Y. Oda, Y. Nakanishi, 2015, Oncotarget.

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Y. Oda, Y. Nakanishi, I. Okamoto, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma

I. Okamoto, Kentaro Tanaka, H. Inoue, 2022, Cancer science.

Paired genetic analysis by next‐generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis

Y. Nakanishi, I. Okamoto, Kentaro Tanaka, 2020, Cancer science.

Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.

Y. Oda, Y. Nakanishi, I. Okamoto, 2021, Lung cancer.

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Y. Oda, S. Anai, Y. Nakanishi, 2018, Lung cancer.

CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.

K. Tsuchihashi, H. Saya, O. Nagano, 2017, Lung cancer.

Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer

Y. Nakanishi, G. Toyokawa, I. Okamoto, 2020, Thoracic cancer.

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

M. Seike, K. Sugio, Y. Nakanishi, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

Y. Nakanishi, K. Azuma, I. Okamoto, 2017, Oncotarget.

NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.

Y. Nakanishi, I. Okamoto, Kentaro Tanaka, 2020, Lung cancer.

Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.

Y. Nakanishi, I. Okamoto, Kentaro Tanaka, 2019, Clinical lung cancer.

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

M. Seike, K. Sugio, Y. Nakanishi, 2019, The oncologist.

Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer

Y. Nakanishi, H. Sasaki, I. Okamoto, 2019, AntiCancer Research.

Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis

S. Matsumoto, K. Goto, I. Okamoto, 2021, Scientific Reports.